World's First Bundibugyo Ebola Vaccine Begins Human Trials

Remarkably, the Oxford team developed the vaccine candidate in just eight weeks after the outbreak was first detected . This rapid development was made possible by leveraging the existing ChAdOx1 platform technology, which had already been proven in both animal and human studies for other diseases . The Serum Institute of India, a major global vaccine manufacturer, partnered with Oxford to produce the vaccine, and has already manufactured and stockpiled approximately 620,000 doses in anticipation of successful later-stage trials and potential emergency use .

The First Human Volunteer: Ed Hunt

The first person in the world to receive the experimental ChAdOx1 BDBV vaccine was Ed Hunt, a 37-year-old man from the United Kingdom . Hunt was dosed in Oxford in late July 2026, becoming the first of 50 healthy volunteers aged 18 to 55 being recruited for the Phase I clinical trial .

The trial, known as BD-Ebov, is being conducted by the University of Oxford's Vaccine Group in Oxford, UK . Its primary objectives are to assess the vaccine's safety and its ability to generate a strong immune response (immunogenicity) . Participants undergo detailed medical screening before receiving the vaccine and are closely monitored afterward .

Why This Vaccine Matters: A Strain with No Approved Countermeasures

The urgency behind the ChAdOx1 BDBV trial stems from a fundamental gap in global health preparedness. There are no licensed vaccines or specific therapeutics approved anywhere in the world for the Bundibugyo strain of Ebola (species Orthoebolavirus bundibugyoense) . This is in stark contrast to the more common Zaire ebolavirus, for which the Ervebo vaccine and other treatments exist .

The World Health Organization (WHO) and global health agencies have recommended that any candidate treatments or vaccines for Bundibugyo be used exclusively within clinical trials to generate robust safety and efficacy data . The ChAdOx1 BDBV Phase I trial is the first human trial of any Bundibugyo-specific vaccine . Other candidates, such as one from IAVI using the rVSV platform (identified by WHO as the most promising pre-clinical option) and one from Moderna using mRNA technology, remain in preclinical or earlier stages of development .

The 2026 Bundibugyo Outbreak: A Public Health Emergency

The clinical trial was launched against the backdrop of a severe and expanding outbreak in Central Africa.

Timeline and Scale

• First detection: The outbreak was first detected in Ituri Province, DRC, in May 2026. Early cases are theorized to have occurred as far back as January-February 2026 .
• Official declarations: The DRC and Uganda declared outbreaks on May 15, 2026 .
• PHEIC declaration: The WHO Director-General determined the outbreak to be a Public Health Emergency of International Concern (PHEIC) on May 17, 2026 .
• Confirmed cases and deaths (as of mid-July 2026): As of July 15, 2026, WHO reported a cumulative total of 2,124 confirmed cases and 828 deaths in the DRC alone, with additional cases reported in Uganda and France .
• Continued spread: The outbreak has spread from Ituri Province to North Kivu, South Kivu, and other provinces in DRC, as well as to neighboring Uganda .

The Pathogen: Bundibugyo Virus

The outbreak is caused by the Bundibugyo virus, a rare species of Orthoebolavirus first identified in Uganda in 2007 . It is immunologically distinct from the Zaire and Sudan species, which is why existing vaccines and treatments are ineffective against it .

What's Next: The Road to a Potential Vaccine

The Phase I trial for ChAdOx1 BDBV is expected to take several months. If the vaccine proves safe and generates a strong immune response, the Serum Institute of India has the capacity to begin mass production and has already stockpiled hundreds of thousands of doses . Subsequent Phase II and III trials, potentially conducted in the affected regions of DRC and Uganda, could follow rapidly to confirm efficacy . Ultimately, if successful, this vaccine could provide the first specific, authorized medical countermeasure against a deadly strain that has, until now, been without one.